StreetInsider.com News Articles

Form 4 GLOBUS MEDICAL INC For: Jun 05 Filed by: Davidar David D

Tue, 09 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260609/26624650.html

Form 4 GLOBUS MEDICAL INC For: Jun 05 Filed by: Davidar David D

Tue, 09 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260609/26624650.html

Piper Sandler Reiterates Overweight Rating on Globus Medical (GMED)

Tue, 09 Jun 2026 08:44:48 -0400

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $115.00 price target on Globus Medical (NYSE: GMED).

The analyst commented: "Next-Gen Excelsius Patent Filing Discovered – Findings Are Very Encouraging; Recently, we came across a new patent filing from Globus with descriptions of a nextgeneration Excelsius robot. We want to be clear that a patent does not always yield a new product (and management would not comment on it specifically). However, the information disclosed appeared extremely robust and detailed – leading us to believe the company could be farther along in the process than we would have thought. Given Medtronic's

Form 4 GLOBUS MEDICAL INC For: Jun 04 Filed by: RHOADS ANN D

Mon, 08 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260608/26618348.html

Form 4 GLOBUS MEDICAL INC For: Jun 04 Filed by: RHOADS ANN D

Mon, 08 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260608/26618348.html

Form 144 GLOBUS MEDICAL INC Filed by: Davidar David D

Fri, 05 Jun 2026 15:15:00 -0400

si-local-file:///var/storage/secattach/20260605/26610726.html

Form 144 GLOBUS MEDICAL INC Filed by: Davidar David D

Fri, 05 Jun 2026 15:15:00 -0400

si-local-file:///var/storage/secattach/20260605/26610726.html

Form 8-K GLOBUS MEDICAL INC For: Jun 03

Thu, 04 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260604/26605794.html

Form 8-K GLOBUS MEDICAL INC For: Jun 03

Thu, 04 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260604/26605794.html

Form SD GLOBUS MEDICAL INC

Wed, 27 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260527/26557910.html

Form SD GLOBUS MEDICAL INC

Wed, 27 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260527/26557910.html

Globus Medical (GMED) PT Lowered to $87 at Freedom Broker

Tue, 19 May 2026 07:39:02 -0400

Freedom Broker analyst Keith Hinton lowered the price target on Globus Medical (NYSE: GMED) to $87.00 (from $92.00) while maintaining a Hold rating.

The analyst comments "GMED reported 1Q26 earnings on May 7 after market close. 1Q results were strong with +2-3%, +7-8% and +17-21% beats vs. our and Street estimates on revenue, EBITDA and EPS, respectively. GMED raised EPS guidance +7% at the midpoint but left revenue guidance unchanged, which we think supports our view that in 2H26 and into 2027, when both sales (particularly US Spine) and margin comps get tougher, Y/Y sales growth is likely to drop to

Globus Medical (GMED) PT Lowered to $87 at Freedom Broker

Tue, 19 May 2026 07:39:02 -0400

Freedom Broker analyst Keith Hinton lowered the price target on Globus Medical (NYSE: GMED) to $87.00 (from $92.00) while maintaining a Hold rating.

Globus Medical (GMED) Reiterated at Market Perform by Citizens After Q1 Results

Mon, 18 May 2026 07:23:29 -0400

Citizens analyst David Turkaly reiterated a Market Perform rating on Globus Medical (NYSE: GMED).

The analyst commented, "We reiterate our Market Perform rating on shares of Globus Medical following the release of 1Q26 operating results. GMED started the year with a period of operational strength, with broadbased growth in Musculoskeletal Solutions and Enabling Tech driving 26% y/y cc growth (+11% y/y cc exNevro) and culminating in an ~3% beat on the top line and an ~22% beat on the bottom. Globus' base business was underpinned by strength in the U.S. Spine channel, which drove revenue growth of 10% y/ y (third

Globus Medical (GMED) PT Raised to $95 at Stifel

Fri, 08 May 2026 07:32:00 -0400

Stifel analyst Thomas M. Stephan raised the price target on Globus Medical (NYSE: GMED) to $95.00 (from $90.00) while maintaining a Hold rating.

The analyst comments "1Q26 sales were relatively solid and above Street—expectedly driven by strong core Musculoskeletal, as ET finished in-line and Nevro deteriorated. Despite the beat, management maintained sales guidance (Nevro offsetting core). • EPS was the 1Q26 standout at $1.12, and guidance increased by $0.30—more than the ~$0.20 1Q beat. • Coming into earnings, we noted we were warming up to the stock—but we still struggle a bit with what to do with shares here. On one

Globus Medical (GMED) PT Raised to $95 at Stifel

Fri, 08 May 2026 07:32:00 -0400

Stifel analyst Thomas M. Stephan raised the price target on Globus Medical (NYSE: GMED) to $95.00 (from $90.00) while maintaining a Hold rating.

Globus Medical (GMED) PT Raised to $120 at RBC Capital

Fri, 08 May 2026 07:31:03 -0400

RBC Capital analyst Shagun Singh raised the price target on Globus Medical (NYSE: GMED) to $120.00 (from $115.00) while maintaining a Outperform rating.

Globus Medical (GMED) PT Raised to $130 at Wells Fargo

Fri, 08 May 2026 06:57:10 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on Globus Medical (NYSE: GMED) to $130.00 (from $104.00) while maintaining a Overweight rating.

Globus Medical (GMED) PT Raised to $117 at Needham

Fri, 08 May 2026 06:18:56 -0400

Needham analyst Mike Matson raised the price target on Globus Medical (NYSE: GMED) to $117.00 (from $114.00) while maintaining a Buy rating.

The analyst comments "GMED's 1Q26 revenue and EPS beat consensus, and management raised its 2026 EPS guidance by ~7% at the mid-point (the 2nd EPS guidance raise this year), which now sits ~4% under the Street's 2027 EPS. The earnings strength is driven by gross margin improvement and organic revenue growth, and despite Nevro's margin contracting sequentially. Given underlying strength in GMED's base business and its strong margin trajectory, we reiterate our Buy rating and raise our price target

Globus Medical (GMED) PT Raised to $117 at Needham

Fri, 08 May 2026 06:18:56 -0400

Needham analyst Mike Matson raised the price target on Globus Medical (NYSE: GMED) to $117.00 (from $114.00) while maintaining a Buy rating.

Globus Medical (GMED) Tops Q1 EPS by 20c ; Offers Guidance

Fri, 08 May 2026 01:47:37 -0400

Globus Medical (NYSE: GMED) reported Q1 EPS of $1.12, $0.20 better than the analyst estimate of $0.92. Revenue for the quarter came in at $759.85 million versus the consensus estimate of $740.34 million.

GUIDANCE:

Globus Medical sees FY2026 EPS of $4.70-$4.80, versus the consensus of $4.47. Globus Medical sees FY2026 revenue of $3.18-3.22 billion, versus the consensus of $3.2 billion.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

Globus Medical (GMED) Tops Q1 EPS by 20c ; Offers Guidance

Fri, 08 May 2026 01:47:37 -0400

GUIDANCE:

Globus Medical sees FY2026 EPS of $4.70-$4.80, versus the consensus of $4.47. Globus Medical sees FY2026 revenue of $3.18-3.22 billion, versus the consensus of $3.2 billion.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

Form 10-Q GLOBUS MEDICAL INC For: Mar 31

Thu, 07 May 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260507/26455047.html

Form 10-Q GLOBUS MEDICAL INC For: Mar 31

Thu, 07 May 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260507/26455047.html

Form 8-K GLOBUS MEDICAL INC For: May 07

Thu, 07 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260507/26453924.html